These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28581126)

  • 1. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs.
    Blasco MA; Svider PF; Raza SN; Jacobs JR; Folbe AJ; Saraf P; Eloy JA; Baredes S; Fribley AM
    Laryngoscope; 2017 Nov; 127(11):2565-2569. PubMed ID: 28581126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of head and neck squamous cell carcinoma.
    Pan Q; Gorin MA; Teknos TN
    Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
    Corvò R
    Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
    Muratori L; La Salvia A; Sperone P; Di Maio M
    Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence.
    Benson R; Mallick S; Julka PK; Rath GK
    J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
    Bernier J; Vrieling C
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
    Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
    Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for head and neck cancer.
    Wen Y; Grandis JR
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):313-29. PubMed ID: 25826749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
    Martinez-Useros J; Garcia-Foncillas J
    Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.